Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 327,356
  • Shares Outstanding, K 98,899
  • Annual Sales, $ 16,490 K
  • Annual Income, $ -60,410 K
  • 60-Month Beta 1.25
  • Price/Sales 20.41
  • Price/Cash Flow N/A
  • Price/Book 2.45
Trade ACIU with:

Options Overview Details

View History
  • Implied Volatility 135.14% ( +6.26%)
  • Historical Volatility 44.04%
  • IV Percentile 77%
  • IV Rank 33.45%
  • IV High 357.22% on 04/19/24
  • IV Low 23.51% on 11/14/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 3,476
  • Open Int (30-Day) 3,318

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.22
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.23
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.95 +14.92%
on 09/12/24
3.98 -14.82%
on 09/23/24
+0.34 (+11.15%)
since 09/09/24
3-Month
2.92 +16.10%
on 09/09/24
4.26 -20.42%
on 07/31/24
-0.10 (-2.87%)
since 07/09/24
52-Week
2.20 +54.09%
on 10/23/23
5.14 -34.05%
on 12/28/23
+0.83 (+32.42%)
since 10/09/23

Most Recent Stories

More News
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 3.39 (+2.42%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 3.39 (+2.42%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 3.39 (+2.42%)
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 3.39 (+2.42%)
Why Shares of AC Immune Jumped This Week

The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.

ACIU : 3.39 (+2.42%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 3.39 (+2.42%)
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 5.87 (-1.51%)
CNCE : 8.37 (+0.12%)
KYKOF : 20.9710 (-0.14%)
SFOSF : 1.8300 (+4.57%)
KHTRF : 4.2600 (-2.29%)
ACIU : 3.39 (+2.42%)
BMEA : 10.90 (-4.39%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 3.39 (+2.42%)
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC

Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences...

ACIU : 3.39 (+2.42%)
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Three clinical readouts delivered year to date; four more expected by year-endFirst patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE...

ACIU : 3.39 (+2.42%)

Business Summary

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta...

See More

Key Turning Points

3rd Resistance Point 3.61
2nd Resistance Point 3.54
1st Resistance Point 3.46
Last Price 3.39
1st Support Level 3.31
2nd Support Level 3.24
3rd Support Level 3.16

See More

52-Week High 5.14
Fibonacci 61.8% 4.02
Fibonacci 50% 3.67
Last Price 3.39
Fibonacci 38.2% 3.32
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar